The development of new anticancer agents, including bio-drugs, is currently a long and costly process, largely due to: —The difficulty in identifying selective molecules and optimising the screening conditions of candidate molecules, -Intratumoral conditions not correctly reproduced on in vitro cell models leading to the failure of certain drug candidates to give the expected results in vivo, while they showed promising activities in the initial in vitro tests, -The appearance of cheioresistance for certain medicinal products linked to the presence of tumor strain cells in their hypoxic niche. Thus, in order to meet a therapeutic need and remove the technological barriers for the study of cancers, the project aims to establish an integrative biotechnological platform based on the development of innovative methodologies for 1) screening and preparation of fragments of antibodies for therapeutic purposes, 2) characterisation of their mechanism of action at the cellular level, in particular on tumour stem cells, and in adapted biomimetic 3D models, integrating tumor stem cells and best replicating the hypoxic tumor niche, and 3)... (...)